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Abstract
Since their discovery over a century ago, sphingolipids have riddled and fascinated the
scientific community with benchmarks of progress including the identification of the enzymatic
defects in the lysosomal storage diseases and the discovery of their involvement in cellular
processes. Excluding sphingosine-I-phosphate with its associated G-protein coupled receptors, a
staggering gap still persists in our understanding of the mechanisms related to the functions of the
sphingolipids, ceramide and sphingosine.

Moreover, in spite of the impressive amount of

literature implicating ceramide in biological processes, precise and well-documented roles in
biology for specific ceramide-producing enzymes are surprisingly rare.

To further investigate the biological role of ceramide, we made the general hypothesis
that ceramide produced from specific enzymes in the salvage pathway of sphingolipid
metabolism plays a role in regulating stress signaling. In this work, we first aimed to identify
novel protein targets of ceramide in the context of serine/threonine phosphatases to address
possible mechanisms of ceramide action in stress signaling, and second to define specific roles
for salvage pathway enzymes in the regulation of IL-6, a proinvasive cytokine. As a result of this
work we identified a novel class of serine/threonine phosphatases, PP2C/PPM, to be activated by
ceramide. This opens a new avenue of research to investigate ceramide-mediated mechanisms in
biology. Additionally, this work demonstrates, essentially for the first time, involvement of the
ASM/ceramide pathway in the activation of p38 signaling, resulting in the induction of IL-6. Our
findings fit with previous work connecting PKC activation to ASM, while casting ASM in a new
light as a potential proinvasive factor in cancer.
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Chapter 1: Introduction to Mechanisms and Roles of Sphingolipids in Stress Signaling and
Interleukin-6 Synthesis

Overview of Sphingolipid Metabolism
Sphingolipids were first discovered by Thudicum, a German-born scientist, In 1884
through his work on the chemical composition of the brain(], 2). Through most of the next
century, sphingolipids were thought to be limited to providing structural or physical properties to
the membrane, but through pioneering studies, certain species of sphingolipids were shown to
have bioactive properties acting possibly as second messengers analogous to diacylglycerol
(DAG)(3, 4).

Since then much effort has been exerted in defining the biological roles of

sphingolipids, especially sphingosine-I-phosphate (S I P) and ceramide, yet clarifying clear
biochemical mechanisms of action for ceramide has been more elusive. Two considerations are
worth noting when dealing with sphingolipids. First, due to their hydrophobicity, sphingolipids
are confined to the membrane except for instances when bound to a protein carrier such as CERT
or in the case of SIP and to some degree with sphingosine being soluble in their own right.
Because of this quality, the interchanging between lipid species occurs exclusively at the
membrane. Secondly, for each class of sphingolipids there is incredible diversity of subspecies
due to variations and modifications such as length of the acyl chain and its hydroxylation(5).

Sphingolipid metabolism is divided into a de novo synthetic pathway beginning with the
condensation of palmitoyl-CoA and serine eventually forming ceramide and a salvage, catabolic
pathway involving the hydrolysis of complex sphingolipids to reform ceramide Fig. (1-1)(6). De
novo synthesis of ceramide occurs in the endoplasmic reticulum (ER), where it can be trafficked
to the Golgi apparatus for synthesis of complex sphingolipids including sphingomyelin (SM) and
glycosphingolipids (GSLs). Once SM and GSLs are made they can be recycled in the salvage
pathway by removal of either phosphocholine by sphingomyelinases (SMases, ASM denotes
Acid SMase) or sugars by hydrolases, where acid (3-glucosidase (GBA) is the last enzyme for the
degradation of GSLs(7). As a result, ceramide is formed, where it is further broken down into
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sphingosine by acid ceramidase (ACD) and neutral and alkaline ceramidases (NCD, ACER) via
removal of the acyl fatty acid. Now the basic sphingoid backbone can be reformed into ceramide
by acylation catalyzed by ceramide synthases to complete the cycle. Alternatively, sphingosine
can be phosphorylated by one of two kinases (SKI/2) to form SIP, a bioactive lipid with
established cognate GPCRs.

Catabolism of Complex Sphingolipids: The Sphingolipid Salvage Pathway
The sphingolipid salvage pathway simply refers to the recycling of sphingolipids. This
involves movement of lipids at the plasma membrane to the lysosome and then eventually to the
ER, but may also occur exclusively at the plasma membrane, Golgi, or elsewhere(8). In a typical
cell, SM and presumably other complex sphingolipids are more abundant than ceramide, and
ceramide more abundant than sphingosine, and so on(6). This system is constructed in such a
way that a small increase in the rate of hydrolysis of complex sphingolipids at the plasma
membrane for example would have large fold changes for ceramide and downstream lipids. The
implications of this are that 1) hydrolysis of SM and glucosylceramide (GC) is an efficient and
rapid way to generate large changes in ceramide and downstream metabolites, and 2)
accumulation of ceramide, sphingosine, and SIP may occur sequentially, in a time-dependent
fashion.

Once ceramide is generated, the likely rate-limiting step for further metabolism is

simply access to a ceramidase since these may be topologically restricted.

Reacylation of

sphingosine to ceramide is the final step in the salvage pathway, completing the 'recycling'
aspect; however, increases in sphingosine are likely to directly affect SIP.

It is not well

understood what regulates the preference of sphingosine for either SK or CerS. Lastly, SIP is in
some sense a committed step towards the exit of sphingolipid metabolism, where SIP lyase
forming hexadecenal and ethanolamine phosphate is the only known reaction to break the
sphingoid backbone, while SIP can also be dephosphorylated back to sphingosine by SIP
phosphatase (SPP).
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Activation of the salvage pathway in response to certain stimuli or stress is a fundamental
concept of sphingolipid signaling. Several reports demonstrate that PMA causes 1) increases in
degradation of complex sphingolipids (SM or GC), 2) increases in ceramide dependent on ASM
or GBA, and 3) increases in sphingosine, all of which are indicators of salvage pathway
metabolism(9-11). PKCb has been shown to be specifically required for the above stimulation of
the salvage pathway for SM and GC hydrolysis. Additionally, other cytokines, such as
TNFa, lead to activation of SM hydrolysis(12). Whether there are unique functions of SM versus
GC catabolism is unknown. It is thought that ceramide produced from either ASM or GBA,
being structurally identical, is also identical in function.

This work begins to address the

possibility that the function of ASM- or GBA-derived ceramide may be functionally distinct (Fig.
1-2).

Acid Sphingomyelinase (ASM)
ASM is a SM phosphodiesterase that has been well studied in terms of genetics,
biochemistry, biological functions, and disease, being mutated in Niemann Pick Disease(13, 14).
It is distinguished from other SMases primarily by its pH optimum of 4.0-5.2, where pH only
affects Km and not catalytic rate(15). The enzymology of ASM is affected by many other factors
as well including the presence of Zn 2+ (particularly for the secreted form)(16), inhibition by
reducing agents(l7), and activation or inhibition by various phospholipids(lB-20). Structurally,
ASM is composed of several distinct domains including a saposin-like domain, a catalytic
phosphodiesterase domain, and a C-terminal domain.

ASM can either be targeted to the

lysosome via mannose-6-phosphorylation or secreted(21, 22), and there is also evidence that it
can translocate to the plasma membrane(9). Activation of ASM by PKCb is associated with
translocation to plasma membrane.
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Acid f:l-Glucosidase (GBA)
Acid

~-Glucosidase

(glucosylceramidase, glucocerebrosidase, GBA, EC= 3.2.1.45) is an

acid hydrolase that catalyzes the reaction of glucosylceramide to ceramide and glucose or
glucosylsphingosine to sphingosine and glucose (23, 24). GBA has been well studied
biochemically and clinically but its roles in cell biology are still emerging. Saposin C and anionic
lipids are both required for full enzymatic activity (25, 26). It appears that the association of
GBA with the membrane is dependent on these two factors also (25). GBA is thought to mainly
reside in the lysosome where the breakdown of glucosylceramide is the last step in the catabolism
of glycosphingolipids to ceramide(27, 28). Structurally GBA consists of three domains. Domain
I is glycosylated and contains disulfide bonds; domain II has an immunoglobulin-like fold, and
domain III contains the catalytic site (29). The crystal structure of GBA has been determined
alone and in the presence of inhibitors and other pharmacological compounds (29-32). One such
inhibitor is conduritol B epoxide (CBE), an irreversible inhibitor of GBA that can be used to
model loss of function experiments (33,34). A non-lysosomal glucosylceramidase (GBA2) has
been identified and is insensitive to conduritol B epoxide (35, 36).

Protein Targets of Ceramide
Despite extensive evidence showing accumulation of ceramide, downstream of ASM or
GBA, exactly how ceramide is mediating its effects or involved in biological processes (e.g.
apoptosis(37) is less well understood. Presumably, there is a direct protein target that interacts
with ceramide and mediates the effects of ceramide accumulation. Evidence for direct targets of
ceramide are in the literature; however, when compared to well known lipid/protein interactions
such as diacylglycerol (DAG) and protein kinase C (PKC), there is a paucity of biochemical
mechanisms for ceramide signaling.
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Previous work from our lab has shown that the protein phosphatases, PPI and PP2A are
activated by ceramide(38).

Early work by Dobrowsky et al. showed activation of cytosolic

phosphatase activity by short and long chain ceramide delivered in ethanol(39). Activation was
specific to ceramide in that SM or sphingosine had no effect on activity. Further work showed
that purified forms PP 1 and PP2A were in fact activated by C 2 -ceramide(40). Chalfant et ale
characterized the structural requirements for activation of PP2A demonstrating that almost all
aspects of cerami de are essential for activation of PP2A including the stereochemistry, 4-5 trans
double bond, sphingoid backbone, and the secondary amide(41). Phosphatidic acid (PA) was
shown to inhibit PPI basal activity yet enhancing the fold-activation by ceramide(38). Taken
together, there is unique and specific interaction between these phosphatases and ceramide.
Recent work by Canals et aI., has shown a specific role for PPla in mediating ceramide-induced
dephosphory lation of ezrin/radixin/moesin family of cytoskeletal proteins upon treatment with
bacterial SMase(42). The finding that PPla was required and not other PPI isoforms,

f3

or y,

demonstrates that despite significant homology these isoforms have nonredundant biological
functions.

Ceramide has been shown to bind to 12PP2A, modulating PP2A and thus

phosphorylation of c-myc(43). Other reported targets of ceramide include Cathepsin D(44, 45),
PKC(;,(46), Raf-I(47) and KSR(48), but there are still significant questions remaining in regard to
these putative targets. A need exists to better understand the nature of the interaction between
ceramide and these proteins and to confirm a clear physiological relevance of this interaction.

Regulation of p38 MAPK signaling and IL-6 Production by Sphingolipids
A core part of the response to stress, including DNA-damaging agents, osmotic stress,
inflammatory cytokines, and oncogenic stimulation, is activation of the stress-activated protein
kinase (SAPK), p38 and JNK of the MAPK family, which are dually phosphorylated at a
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conserved Thr and Tyr motif in the activation 100p(49). As a result of this phosphorylation,
kinase activity

IS

activated resulting in phosphorylation of downstream targets (50) .

The

subcellular localization of p38 is thought to be both cytosolic and nuclear, where there is not a
clear nuclear translocation distinguishing it from ERK(50, 51).

The family of p38 MAPK

consists of four isoforms a/f)/y/6 where these may have some overlapping functions and also
unique roles. One of the canonical functions of p38 is the production of inflammatory cytokines
such as IL-6 in response to LPS or TNF through activation of transcription factors and
stabilization of mRNA(52-55). However, the biological outcome of p38 signaling is diverse,
often with paradoxical effects depending on factors such as duration or amplitude of signal and
the genetic background of cell type. Therefore, since ceramide and p38 are both involved in the
cellular response to stress, is there crosstalk between these systems in the cell?

In the literature there is varied evidence in regard to regulation of p38 signaling by
ceramide. Several studies utilized treatment of exogenous ceramide at early(56, 57) or late time
points(58) , which is thought to mimic endogenous accumulation of ceramides but still is a
nonspecific tool in that cerami de can be made from several enzymes possessing potentially
unique functions.

The above reports show modest increases in p38 activation in response to

either exogenous ceramide or sphingomyelinase.

Other groups using ASM-1- mouse

macrophages(59) or human Niemann Pick Disease fibroblasts (60) showed a lack of an effect on
p38 phosphorylation in ASM loss of function cells. There is an association between activation of
SMase activity and activation of p38 and ERK, but a causal relationship is not well demonstrated.
In general this work (above) primarily was focused on the positive role of ceramide in p38
activation.

However, more recent work by Kitatani et al. demonstrated that inhibition of

ceramide synthase (CerS) with Fumonisin B 1 resulted in augmented p38 activation in response to
PMA suggesting that ceramide may be negatively regulating p38(61).
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Evaluation of other

ceramide producing enzymes resulted In the finding that knockdown of GBA with siRNA
resulted in a similar phenotype( 62).

Measuring the production of IL-6 is a convenient and physiologically relevant readout of
p38 signaling. Indeed there are reports of sphingolipids, specifically ceramide and the SM cycle
being involved in the elaboration of IL-6 and other cytokines. Early evidence demonstrated that
either exogenous ceramide or SMase was sufficient to induce IL-6 in fibroblasts( 63), endothelial
cells(12), lung epithelial cells(64), and astrocytoma cells(65), suggesting that increasing ceramide
levels in the cell was able to trigger endogenous signaling mechanisms. Sakata et al. implicated
ASM in IL-6 production in response to LPS in macrophages using a SMase inhibitor, SMA7(66); LPS was shown to activate ASM and elicit increases in cerami de at 3 hr, both of which
were blocked by treatment with SMA-7. This inhibitor apparently also inhibits nSMase2 and has
not been used elsewhere as a specific ASM inhibitor. Recent work by Kumagai et al. showed that
electrophilic pollutants (e.g. diethyl malate) lead to upregulation of ASM message and enzymatic
activity in bladder cancer cells, which plays a role in these compounds' ability to augment IL-6
when cotreated with TNFa(67). Desipramine (an in vivo ASM inhibitor) or ASM siRNA only
reduced IL-6 when cells were treated in combination with diethyl malate and TNFa but not with
TNFa alone. Conversely, in MCF-7 breast cancer cells, treatment of GBA siRNA resulted in an
increase in IL-6 production in response to PMA, which was shown to be p386-dependent(62).
Exogenous ceramide dose dependently blocked PMA-induced IL-6 in GBA and control siRNA
treated cells. Other cytokines and chemokines have been studied in light of sphingolipid enzymes,
where Jenkins et aI., showed the requirement of ASM and ACD for the production of

CCL5/RANTES mRNA and protein(68). Also desipramine has been reported to lead to increased
IL-8 levels contrasting to its effect on RANTES(69). Taken together the roles of specific
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ceramide producing enzymes are only beginning to be defined in their contribution to IL-6. To
date, there is no study comparing different sphingolipid enzymes in the regulation of IL-6.

Lysosomal Storage Diseases
Inherited genetic defects in several of the enzymes involved in the sphingolipid salvage
pathway lead to lysosomal storage diseases; for example, mutations in GBA, ASM, and ACD,
result in Gaucher, Niemann Pick, and Farber disease, respectively(70, 71). Emerging evidence
suggests that these diseases do not simply arise from an accumulation of excess lipid leading to
cellular toxicity, challenging the long-standing dogma(72, 73). While lipid accumulation may
account for a portion of clinical manifestations in more severe cases, it is clear that even
heterozygous loss of GBA, which is not associated with Gaucher disease, results in predisposition
to Parkinson disease( 73), suggesting that these enzymes and their metabolized product, ceramide,
are critically involved regulation of cellular processes.

Niemann Pick Disease
Mutations in the gene of SMPDl, encoding ASM, lead to Niemann Pick Disease (NPD)
Type A and B(74-77). Type A is the more severe disease with neurological involvement with a
life expectancy of 2-3 years. Type B may diagnosed in childhood or into adulthood, where it is
thought that differences in residual ASM activity account for onset of Type A or B, Type A
associated with less ASM activity(7, 78).

NPD is associated with hepatosplenomegaly,

lymphadenopathy, osteoporosis, and cherry red maculae. Histologically, foam cells are found,
which are macrophages engulfed with SM and possibly other lipids. There are reports of lung
involvement in Type B disease(79). Even though there has been much research performed on the
function of ASM including work done in cells from patients and model mice demonstrating
resistance to apoptotic agents( 80) there seems to be little overlap in terms of clinical findings in
NPD. Since these reports implicate ASM as a mediator of cell death, it would be expected that
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NPD patients or carriers would be at increased risk of developing cancer; however, due to the
shortened lifespan of NPD patients this may not present clinically. Additionally, based on the
involvement of ASM in cytokine production it is possible that patients may be more susceptible
to certain infections, which may be consistent with pulmonary findings in NPD. In line with this,
ASM deficient mice are associated with increased susceptibility to Listeria monocytogenes;
however, the pathogenesis of this is not well understood nor is the clinical pulmonary phenotype
well characterized(81).

Gaucher Disease
Gaucher disease is the most common lysosomal storage disease caused by homozygous
mutation in GBA of which a few hundred are known (82-86). There are three types of Gaucher
disease classified clinically; type 1 is non-neuronopathic consisting of variable visceral disease,
type 2 is neuronopathic with severe neurodegeneration leading to death at a young age, and type 3
is similar to type 2 but milder. Gaucher disease is composed of a constellation of symptoms and
comorbid

diseases

including

associations

with

hematologic

malignancies,

pulmonary

hypertension, and parkinsonism, which makes the study of Gaucher disease pathophysiology
applicable to a much broader set of patients than those strictly with Gaucher disease (70, 87-89).
Generally the disease is characterized by bone pain, hepatosplenomegaly, pulmonary disease,
chronic fatigue, and in neuronopathic forms by oculomotor defects, hypertonia, seizures,
dementia, and progressive brainstem degeneration (90, 91). Also there is a fever associated with
these patients that is unattributable to any infection (91). The severity and variety of symptoms
vary widely between patients even among the same genotype (92) although there are some
general genotype-phenotype correlations, but they are not strict associations. Interestingly it is
known that patients with Gaucher disease have increased rates of Parkinsonism (93, 94).
Conversely Parkinson's disease patients have increased frequency of heterozygous mutation of
GBA with an odds ratio of 5.43 (73). Heterozygous mutation in GBA is the strongest genetic
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association in Parkinson's disease currently known suggesting that loss of GBA activity is an
etiological or predisposing factor.

Pathogenesis of Lysosomal Storage Diseases
Accumulation of GC resulting in the formation of lipid crystals in Gaucher disease or SM
in NPD in the lysosomes of macrophages has been viewed as the primary insult resulting in
pathology. The unmetabolized lipid accumulates in lysosomes of the reticuloendothelial system,
namely

macrophage-derived

cells

leading

to

the

formation

of

'Gaucher

cells,'

the

pathopneumonic finding in Gaucher disease (95, 96). The accumulation of glucosylceramide and
formation of Gaucher cells or in the case of SM and foam cells in NPD, indeed does occur in the
human disease, but the pathophysiological consequence of this is not well understood.

There are several publications documenting altered cytokine levels in Gaucher patients
(97-101). Most report increased IL-6 and TNFa (97, 99, 100); however there are reports that did

not detect any change in these but in other cytokines including M -CSF, IL-8, and sCD 14 (98).
Also fetal brain from GBA knockout mice showed increased cytokine expression including
TNFa, IL-6, IL-la, and IL-l(3, and microglial cells from the brainstem and cerebellum had
increased ROS (102).

All these studies have shown an increase in various cytokines or

inflammatory markers in Gaucher disease. More recent data (discussed below) in conjunction
with previous knowledge of the pathology warrant a reconsideration of the accepted view of
pathogenesis of Gaucher disease. The longheld paradigm that loss of GBA leads to dysfunctional
macrophages which then the body attacks resulting in chronic, systemic inflammation, lacks
explanation of many observations from in vivo and in vitro studies.
One line of evidence is from a mouse model of Gaucher with the L444P mutation. The
mIce were reported to have multi-system inflammation, yet were without accumulation of
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glucosylceramide in brain, spleen, and liver (in only one mouse were any lipid-laden
macrophages found) (72). The remaining acid (3-g1ucosidase activity ranged from 15-20% in
several tissues.

In spite of this high residual activity and the lack of accumulation of

glucosylceramide, noticeable pathology was observed including widespread lymphadenitis with
follicular hyperplasia, signs of plasmacytosis, and dermis and pulmonary infiltrate accompanied
by increased TNFa mRNA in the liver and IL-l(3 in lymph nodes.

Secondly, mesenchymal

stromal cells from Gaucher patients compared to control had increased mRNA for IL-8 and COX2 (103).

Additionally, control MSCs treated with CBE had increased levels of IL-8 mRNA.

Thus even in an ex vivo/in vitro setting loss of GBA activity whether genetic or pharmacological
altered mRNA expression of an inflammatory chemokine (104).

Lastly, the finding that

heterozygous mutations in GBA are associated with Parkinson's disease is a very intriguing
finding (73).

One could speculate that heterozygous mutation of GBA is unlikely to lead to

accumulation of glucosylceramide to pathological levels, since heterozygotes retain a significant
fraction of GBA activity(1 05).

Since even partial loss of acid glucocerebrosidase activity

predisposes to an inflammatory, neurodegenerative disease, salvage of glycosphingolipids
through GBA eventually to ceramide may have an anti-inflammatory role. Alternatively, there is
little known about heterozygous carriers of ASM mutations and there susceptibility or resistance
to certain conditions. It is probable that carriers of mutations in either GBA or ASM may reveal a
defect in the physiological role of these enzymes over the homozygous condition where it is
essentially impossible to dissect storage-related issues from signaling or cellular biology-related
defects in the homozygous condition alone.
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Chapter 2: Identification and Characterization of PP2C Activation by Ceramide

Introduction

Sphingolipids are an enigmatic class of membrane lipids implicated as mediators in
several biological processes(6). Ceramide, the central sphingolipid metabolically, has been well
studied and is known to be important in apoptosis(106-108), differentiation(109), and
inflammation(68, 110). Despite the vast amount of evidence for the involvement of ceramide in
biological processes, a clear mechanistic understanding of how ceramide mediates these effects is
not well grasped. However, there are a few emerging biological targets for ceramide such as
protein kinase C(;,(46, 111) and protein phosphatases 1 (PPI) and 2A (PP2A) based on evidence
that PPI and PP2A are activated by ceramide in vitro in a selective and stereospecific manner(38,
41).

Biological targets of ceramide-activation of these phosphatases include retinoblastoma

protein (112), ezrin/radixin/moesin(113, 114), SR proteins(115), and p38(61, 62). However other
Serine/Threonine (Ser/Thr) phosphatases have not been ruled out as ceramide-activated.

Ser/Thr phoshoprotein phosphatases are comprised of three families: phospho-protein
phosphatases

(PPP) ,

metal-dependent

phosphatases

(PP2C/PPM),

and

FCP/SCP-like

phosphatases(116). PP2C phosphatases can be biochemically distinguished from PPPs by their
insensitivity to Okadaic acid (OA), a potent inhibitor of PP2A and PP1(117, 118). The PPP
family is comprised of at least 10 catalytic subunits (e.g. PPICa), and functional specificity of
the PPP family is thought to arise from their ability to interact with numerous regulatory subunits
potentially dictating substrate specificity and subcellular localization(119). In contrast, the PP2C
family is comprised of at least 16 distinct catalytic genes in humans (120) where an internal
regulatory domain may govern substrate specificity and subcellular localization. Despite a lack
of sequence homology, there is a similar 3-dimensional architecture between PPI and PP2Ca
with a central

~-sandwich

surrounded by a-helices(121).
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In an effort to further characterize the relationship between ceramide and Ser/Thr protein
phosphatases, we identified PP2Cy/PPMIG in a high salt eluting fraction from a Mono-Q column
as ceramide-activated. Further characterization was performed on PP2Ca, the canonical PP2C
isoform, showing activation in a stereospecific and selective manner. This work has potential
impact on the current understanding of the molecular mechanisms by which ceramide mediates
biological outcomes, implicating PP2Ca as a potential target of ceramide signaling.
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Materials and Methods

Ma teria ls- Frozen rat brains were purchased from Pel-Freez Biologicals and A549 cells were
from ATCC (Manassas, VA). Protein Kinase A (PKA), Myelin Basic Protein (MBP) and other
general chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

PP2A and PPI

antibodies for the catalytic subunits were from BD Biosciences (Franklin Lakes, NJ) and Santa
Cruz Biotechnology (Santa Cruz, CA) respectively. Active-p38 (phospho) antibody and p386
antibodies were from Promega (Madison, WI) and R&D Systems (Minneapolis, MN)
respectively. Radiolabeled y_ 32p_ATP and y_ 33 p_ATP were from Perkin Elmer (Waltham, MA).
C 6 -ceramide, dihydro-D-erythro-C 16 -ceramide, D-erythro-sphingosine, and D-erythro, D-threo,

L-erythro, L-threo-C 16 -ceramides were prepared as described previously(41). C1s-ceramide was
purchased from Matreya (Pleasant Gap, PA).

I-deoxy-C 16-ceramide and dipalmitoyl-glycerol

were purchased from Avanti Polar Lipids (Alabaster, AL). Recombinant PP2Ca and p386 were
purchased from ProSpec (East Brunswick, NJ) and Enzo Life Sciences (Farmingdale, NY)
respecti vely .

Fractionation of Endogenous Phosphatases- In order to identify novel of targets of ceramideactivated phosphatases from human sources, A549 lung cancer cells were used, and lysates were
used immediately after lysis, compared to previous work which used frozen tissue. Frozen rat
brains were used as well to be able to compare to previous work and corroborate findings from
A549 cells. Fractionation was performed as described previously(40). Total homogenate from
A549 cells (-- lOT 150 flasks) or one rat brain was prepared by nitrogen cavitation or passing
through a tight-fitting 7 mL Wheaton dounce in lysis buffer containing 50 mM Tris HCI pH 7.4, I
mM EDTA, 1 mM EGTA, I mini-protease inhibitor tablet/IO mL (Roche, EDTA free).
Homogenate was cleared by centrifuging at 1,000 g for 5 minutes to remove debris and nuclei.
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Supernatant was transferred to high-speed tubes and centrifuged at 100,000 g for 1 hr. All steps
were performed on ice or at 4°C.
Soluble lysate was mixed with 5 M NaCI sufficient to bring to a final concentration of 1.5 M
NaCl.

This was loaded onto a phenyl sepharose column and eluted by decreasing salt

concentration to 0 M N aCl. Fractions were tested for phosphatase activity in the absence or
presence of C 6 -ceramide. Aliquots were also stored for total protein staining or immunoblotting
after SDS-PAGE.

Fractions eluting from ,..,0.5 M through 0 M NaCI were pooled (0.5

mL/fraction), diluted to 50 mM NaCI (50 mL maximum), and then loaded onto a Mono-Q
column. This was then eluted by a linear gradient of 50 mM N aCI to 500 mM N aCl. Fractions
were then tested for phosphatase activity in the absence or presence of C 6 -ceramide and then
aliquotted for Coomassie staining and immunoblotting.

Radiolabeling of MBP- Myelin basic protein (MBP) was phosphorylated by protein kinase A
(PKA) as described previously(40, 41). Briefly, in two identical reactions, 1 mg of MBP was
incubated with 200 U of PKA, 1 mM ATP, 50 J..lCi of either

32p

y- or 33p y-ATP, 10 mM MgCI 2 , 5

mM DTT, 10 mM (3ME in a final volume of 500 J..lI of 50 mM Tris-HCI buffer pH 7.4 for 2 hr at
37°C. This was then precipitated with 170 J..lL of TCA (-20°C) on ice for 10-30 minutes and
centrifuged at 15,000 g for 15 minutes.

The supernatant was discarded and the pellet was

resuspended in 500 J..lL of 40 mM Tris-HCI pH 7.4. This was repeated a minimum of three times
to effectively remove unincorporated A TP.

Phosphatase Activity Assays- Phosphatase assays were performed as described previously(41)
with minor modifications. Briefly, ceramides and other lipids were dissolved in either ethanol or
dodecane/ethanol (2%/98% v/v), which were added to assay buffer (50 mM Tris pH 7.4, 20%
glycerol, 1 mM MnCI 2 , 100 mM NaCI, 1 mM DTT) not exceeding 1% of total volume and
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preincubated for 5 minutes at 30°C. For testing activity from FPLC fractions, 2-5 I-ll of each
fraction was incubated for 15 minutes (phenyl sepharose fractions) or 1 hr (Mono-Q fractions)
with radiolabeled MBP. For assays with PP2Ca, 5-10 ng of enzyme diluted in assay buffer was
incubated in assay buffer for 30 minutes. Termination of the reaction was achieved by adding
375 I-lL of cold 55% TCA followed by 275 I-lL of 0.9 mg/mL BSA. Tubes were capped, vortexed,
and incubated for 15 minutes on ice. Samples were then centrifuged for 30 minutes at 4°C from
which 250 I-lL of the supernatant was transferred to scintillation vials for measuring radioactivity
as a readout of hydrolyzed phosphate. Statistical and kinetic analysis was performed with
Prism/GraphPad using nonlinear regression analysis for calculating kinetic parameters.

Protein Staining and Western Blotting- Fractions were prepared for SDS-PAGE by freezing 0.3
mL at -80°C and subsequent lyophilization overnight.

Samples were then resuspended in

Laemmli buffer and run on SDS-PAGE for total protein staining or western blots on
nitrocellulose membranes and were incubated overnight with primary antibodies in 5% nonfat
milk in PBS/OJ % Tween 20. Membranes were washed in PBS/OJ % Tween 20 at least 3 times,
incubated

with

secondary

antibodies,

washed

again,

and

then

developed

In

ECL

chemiluminescence reagent.

Proteomic Analysis- Fractions of interest were precipitated by adding 0.9 mL cold 100% acetone
to 0.3 mL of each fraction and incubated at -20°C overnight. Samples were centrifuged for 20
min at 45,000 g at 4°C. Supernatants were aspirated and then pellets were dried and stored.
Acid-dissolved Trypsin Gold was diluted to 20

~g/ml

and added to the solubilized pellet and

incubated overnight at 37°C for full digestion. The next day, solution was dried in SpeedVac for
2-4 h in preparation to full dryness then re-solubilized with 50% acetonitrile/5% at room
temperature for MS analysis.
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An instrument set of liquid chromatography (LC)-electrospray ionization (ESI)-tandem mass
spectrometry (MS/MS) on a linear ion trap mass spectrometer (LTQ, Thermo Finnigan) coupled
to an LC Packings nano-LC system was used to analyze the trypsin-digested sample. For reversed
phase LC column, a 15-cm x 75 J-Lm C-18 (packed by the Proteomics Core Facility, Medical
University of South Carolina) was utilized with a 60-min gradient from 2% acetonitrile, 0.1 %
formic acid to 60% acetonitrile, 0.1 % formic acid at a flow rate of 200 nllmin. A between
samples blank was analyzed to limit carryover. In the mass spectrometer an MS/MS was
performed on all ions above an ion count of 1000 using data-dependent analysis. Dynamic
exclusion mode was set to exclude ions from MS/MS selection for 3 min after being selected two
times in a 30-s window.
The MS/MS data search was performed against mammalian databases using Thermo Finnigan
Bioworks 3.3 software. Data search was also set to account for post-translational modifications of
methionine oxidation, carboxamidomethylation of cysteines, and phosphorylation of serine,
threonine, and tyrosine.

Dynamic Light Scattering-

Varying concentrations of C 16-ceramide were prepared in

dodecane/ethanol (2%:98%). This solution was added to activity assay buffer 1: 100 (v:v) and
analyzed by dynamic light scattering for measurement of particle size using a PDDLSI Cool
Batch 40TI PD2000 DLS. Settings for measurement included 20°C, 0.01769 P and a refraction of
1.35749.
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Results

Screening of Endogenous Phosphatases Reveals PP2Cy as Ceramide-ActivatedIn an attempt to characterize the in vitro activation of Ser/Thr phosphatases by ceramide,
the approach developed by Galadari et al. was employed( 40). Soluble lysate from A549 cells or
rat brain was fractionated first on a phenyl sepharose hydrophobic exchange column and then
subsequently on a Mono-Q anionic exchange column. After each column, fractions were tested
for phosphatase activity in the presence or absence of C 6 -ceramide (ethanol vehicle) using
radiolabeled 32Pi_MBP as a substrate.

Basal phosphatase activity eluting from the phenyl

sepharose column is characterized by a large peak, which generally correlated with the presence
of PP2A according to immunoblots for the catalytic subunit (Fig. 2-1 and 2-2).

As known

previously, this activity was stimulated by ceramide roughly two-fold, with particular fractions
demonstrating unique sensitivity suggesting specific ceramide sensitive targets, ruling out that
this was a general effect. Fractions corresponding to 0.5 M NaCI and later were pooled, diluted,
and loaded on a Mono-Q column.

Phosphatase activity derived from A549 eluting from the Mono-Q displayed three peaks
of activity (Fig. 2-1A right panel. Peak 1- fr 72, Peak 11- fr 77-78, Peak 111- fr 86). The first two
peaks correlated with the presence of PP2A by immunoblot, with peak II being clearly activated
by ceramide (Fig. 2-2A right panel). The two different pools of PP2A are likely a result of
specific heterotrimers with unique B subunits(40) conferring differing anionic character.
Interestingly, a third peak of low basal activity was observed that lacked PP2A yet was
consistently activated by C 6-ceramide.

None of the PPI isoforms (a/(3/y) was detectable by

immunoblot (data not shown), suggesting a previously undescribed ceramide-activated
phosphatase.
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In order to determine whether this phosphatase was in the PPP family, fractions
representing peak II and III off the Mono-Q from A549 were analyzed for their sensitivity to OA
and ceramide. OA strongly inhibited the PP2A-rich peak II as expected and largely blocked the
ceramide activation. In contrast, peak III, which displayed low basal activity, was very sensitive
to ceramide stimulation but insensitive to OA in the absence or presence of ceramide (Fig. 2-2C).
These results were consistent with the possibility that the phosphatase in peak III was a
previously uncharacterized ceramide-activated protein phosphatase.

Corresponding fractions to peaks I, II, and III were observed from the Mono-Q in rat
brain although separation between peaks was less than with A549 lysate (Fig. 2-1 B right panel).
In order to ascertain the identity of the phosphatase in peak III, LC/MS/MS proteomic analysis
was performed on fraction 83 from the Mono-Q using rat brain (Fig. 2-1A right panel). Two
peptide fragments were identified with high confidence matching to PP2Cy/PPM 1G (Table 2-1),
which were specific to this fraction, raising the possibility that PP2Cy was responsible for the
ceramide-activation of phosphatase activity in peak III. Total protein staining of SDS-PAGE was
unable to detect a band in the expected MW range for PP2Cy in this fraction most likely due to
low abundance (data not shown). The PP2C/PPM family of protein phosphatases is metal iondependent and insensitive to OA, fitting with the finding that peak III was insensitive to

~A.

Moreover, PP2Cy possesses a strongly acidic domain not found in other Ser/Thr phosphatase.
This corroborates the finding that peak III corresponds to a high salt eluting fraction due to its
strong acidic domain yielding a predicted overall pI of 4.36. This is consistent with previous
work when it was originally cloned and purified from a Mono-Q column where it also eluted at a
similar N aCI concentration(ll7).
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Activation of PP2Ca by Short Chain and Natural CeramidesBased on the previous finding we hypothesized that PP2Ca is a novel ceramide-

activated phosphatase, which may function as a mediator of ceramide regulation of p38. To first
test whether PP2Cu was also activated by ceramide in vitro, purified recombinant PP2Ca was
assayed in the presence of 30

~M

C 6-ceramide delivered in ethanol or dodecane/ethanol

(2%/98%) as a delivery system since this is the vehicle of choice for long chain ceramides in vitro

(Fig. 2-3A and 2-3B).

Both systems resulted in activation of PP2Ca.

Similar results were

obtained with other long chain and very long chain ceramides (data not shown). Taken together
ceramide

was

able

to

strongly

activate

PP2Ca

whether delivered

with ethanol or

dodecane/ethanol.

A dose response with C 16-ceramide was performed on PP2Ca using dodecane/ethanol
revealing an EC 50 of activation of 5.3

~M

(Fig. 2-3C). The lack of linearity with increasing

ceramide concentrations on PP2Ca activity suggested a dynamic process was occurring between
4-10 J.,tM. To investigate whether this activation was simply a result of particle formation in this
range, dynamic light scattering was performed under similar conditions on dodecane/ethanol with
increasing C 16-ceramide concentrations (Fig. 2-3D). Dodecane/ethanol alone at 1% v/v in activity
assay buffer formed particles, and upon addition of ceramide an increase in particle size was
observed, which modestly continued for 5 and 10

~M.

Due to a lack of a dynamic change in

particle size in the range where activation of PP2Ca was seen, it is unlikely that activation by
ceramide is simply the result of lipid particle formation.

Effect of Ce ram ide on Kinetic Parameters of PP2CaNext, the effects of cerami de on kinetic parameters of PP2Ca were evaluated.
ceramide strongly increased V max while having a minor but notable increase in
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Km

C 16-

(Fig. 2-4A,

Table 2-2). Overall, there was an increase in kca/Km by 3.1 fold. In order to determine whether
ceramide regulates the affinity for the metal cofactor, PP2Cu activity was measured at increasing
concentrations of MnCl 2 in the absence or presence of 10

~M

C l6 -ceramide (Fig. 2-4B). C 16 -

ceramide resulted in an expected increase in V max with no significant change in KA for MnCl 2
(Table 2-3). This shows that ceramide does not regulate the affinity of PP2Cu for its substrate or
cofactors but directly activates the enzyme, likely by allosteric change in the conformation of
PP2Cu.

Lipid Specificity of ActivationCeramide has chiral centers at carbons 2 and 3, yielding four stereoisomers. Evaluation
of the enantiomer and diastereomers of D-erythro-C 16-ceramide demonstrated that the erythro
conformation (both D-erythro- and L-erythro) was required for activation of PP2Cu, and the
threo conformation inhibited activity (Fig. 2-5A).

Other structural variants of ceramide were evaluated to assess the structural requirements
for activation of PP2Cu by ceramide.

Sphingosine, which lacks the acyl chain, resulted in

inhibition of PP2Cu (Fig. 2-5B. The primary hydroxyl at position 1 proved to be essential for
activation due to I-deoxy-C 16 -ceramide having no effect on activity (Fig. 2-5B).

Ceramide

possesses a unique trans double bond at position C4-5, which appeared to not be essential for
activation, as dihydro-C 16 -ceramide was still capable of activation albeit to a lesser extent (Fig. 25B. This is distinct from the near lack of activation of PP2A and PPI by dihydro-ceramides(41).
It has been reported that unsaturated fatty acids are able to activate PP2Cu at high

~M

to mM

concentrations in DMSO(122). In our system, the saturated and unsaturated fatty acids, palmitate
and oleate, respectively both showed inhibition of activity at 8.5 ,.,.,M (Fig. 2-5C) as well as at
higher concentrations (data not shown). In order to assess whether this activation is specific to

2S

the sphingoid backbone, the glycerolipid, dipalmitoylglycerol (DAG) was compared to C 16 ceramide. DAG also displayed activation but was significantly less than C 16-ceramide (Fig. 2-

5C). Overall, the results demonstrate stereochemical and structural specificity and selectivity in
regulation of PP2C by ceramides demonstrating the headgroup of ceramide to be the critical
region for activation.

Ceramide-dependent Dephosphorylation of p38b by PP2C aThe stress-activated p38 MAP kinase is a well-known in vivo and in vitro substrate for
PP2Cu(123, 124), Lack of phosphorylation at Thr182 in the activation loop of p38 was sufficient
to completely inactivate p38a(125, 126), implicating this as a possible mechanism for regulation.
Previous work from our laboratory has shown that p38 activation is regulated by endogenous
ceramide where the p386 isoform is preferentially targeted(61, 62).

Therefore, using

phosphorylated p386 as a phospho-substrate, ceramide-activation of PP2Ca was evaluated at
varying doses in dodecane/ethanol (Fig. 2-6).

PP2Ca alone did not dephosphorylate p386

noticeably; however, the presence of low j.!M concentrations of ceramide caused a robust
dephosphorylation of p386.

These results demonstrate that ceramide stimulates PP2Ca to

dephosphory late p3 86.

26

Discussion

In this study PP2C was discovered to be a novel ceramide-activated protein phosphatase.
Using A549 human lung adenocarcinoma cells and rat brain as sources of soluble lysate, a
fraction, with relatively low basal activity and devoid of known CAPPs, was activated by C 6 ceramide and later identified by LC/MS/MS from rat brain to be PP2Cy. In order to further study
this interaction the canonical PP2C isoform, PP2Ca/PPMIA, was used. Both PP2Cy and PP2Ca
were activated under similar conditions by C 6 -ceramide delivered in ethanol.

C l6 -ceramide

resulted in a robust increase in catalytic activity of PP2Cu, where this activation was
stereospecific.

Lastly, PP2Ca induced the dephosphorylation of p386, a known physiologic

substrate of PP2C, only in the presence of C I6 -ceramide.

This work demonstrates that PP2Cu is robustly and specifically activated by ceramide in

vitro.

PP2Ca was strongly activated by C 6 -ceramide whether delivered in ethanol alone or

dodecane/ethanol demonstrating that dodecane itself was not necessary for activation but possibly
enhancing delivery. Moreover, dodecane/ethanol is likely to be more physiological where lipid
surfaces or particles are being made; however, the exact nature of this structure is unknown.
Within the sphingoid structure, there was remarkable specificity for ceramide on the activation of
PP2Ca. Structure/function studies revealed a requirement for the presence of the acyl chain,
primary hydroxyl group, and erythro conformation. Moreover, the lack of activation by saturated
or unsaturated fatty acids and the diminished activation by DAG compared to ceramide
demonstrate the ceramide/PP2Ca interaction to be rather specific. This raises the possibility that
there is a unique cavity or pocket in PP2Ca able to sense and respond to ceramide, possessing a
hydrophobic pocket with polar residues in the core able to interact with the hydroxyl group and
amide of ceramide.
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Due to the lack of correlation of activity to particle size, ceramide more likely binds
specifically to PP2Cu, provoking an allosteric change rather than nonspecific particle formation
resulting in activation. This is further supported by the evidence that threo stereoisomers did not
activate (Fig. SA). Standard lipid/protein overlay assays were unsuccessful in detecting binding
between ceramide and PP2Cu, an assay that is known not to be well suited for neutral lipids (data
not shown). Additionally, conventional methods of delivering lipids, liposomes/micelles, did not
result in strong changes in activity (data not shown), suggesting a unique lipid delivery
requirement for cerami de to be bioactive in this context such as the requirement for more soluble
monomeric ceramide. In summary, the exact nature of the ceramide/PP2Ca interaction is not
understood, and further studies are needed in this regard.
Lastly, PP2Cu was virtually unable to dephosphorylate p386 in the absence of ceramide (even at
high concentrations of PP2Ca which are known to have high activity towards MBP). However,
in the presence of low

~M

concentrations of ceramide, there was almost complete

dephosphorylation of p386. This suggests that with a more physiological phospho-substrate,
activation by ceramide may be a direct and robust mechanism for regulation.

Accumulating evidence that implicates PP2Ca in responses that are known to be
regulated by sphingolipids, suggesting cellular connections.

First, several lines of work

demonstrate that p38 is regulated by the salvage pathway of sphingolipids where ceramide is
likely a negative regulator of p38 phosphorylation(61).
enzymes, GBA (acid

~-glucosidase)

Inhibition of ceramide-producing

and CerS (ceramide synthase), resulted in enhanced

phosphorylation of p38, and conversely, exogenous treatment of cells with C 6 -ceramide caused a
decrease in p38 phosphorylation induced by phorbol I2-myristate I3-acetate (PMA) in MCF-7
cells(61,62). PP2Ca is a key phosphatase of this pathway, known to dephosphorylate ThrI82 of
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p38.

This model is consistent with our in vitro data suggesting that ceramide-activation of

PP2Ca may be an acute mechanism of negative regulation of p38 signaling. Second, SMAD2/3
IS

regulated

by

sphingosine-I-phosphate

and

dihydro-sphingosine-I-phosphate

(127).

Interestingly, these two lipids have opposite effects on SMAD phosphorylation, which may be
mediated through PP2Ca, an essential SMAD2/3 phosphatase.

The role of ceramide in this

context has not been evaluated where it is possible that ceramide is a negative regulator of SMAD
phosphorylation via PP2Ca activation.

In conclusion, this study demonstrates a novel connection between ceramide and the OAinsensitive phosphatase family, PP2C.

Further study is necessary to probe the physiological

significance of this finding in the context of stress signaling.
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Fig. 2-1. Ceramide-activation of Serine/Threonine phosphatase activity in fractions from phenyl
sepharose and Mono-Q columns. Soluble lysate from A549 (A) or rat brain (B) was fractionated
over phenyl sepharose columns with a gradient from I.5M to OM NaCl. Fractions were
subsequently assayed for phosphatase activity as described in 'Experimental Procedures' in the
absence or presence of 15,...,M C6-ceramide. Fractions consisting of O.5M to OM N aCI were
pooled and diluted to approximately 50mM NaCI, and then loaded onto a Mono-Q column.
Proteins were eluted by a linear gradient from 50mM NaCI to 500mM NaCl. Subsequently
fractions were assayed in the absence of presence of 15,...,M C6-ceramide. Results are
representative of at least 3 independent experiments.
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Aliquots of corresponding fractions were prepared for western blotting for PP2Ac. B, Fractions
77 and 86 (peaks II and III) from A549 eluted from the Mono-Q (Fig. lA) were tested for
sensitivity to Okadaic acid (lOOnM) and C 6 -ceramide (15~M).

Table 2-1
Peptide Fragments of PP2Cy in Peak III (Fr 83) from Rat Brain Identified by LC/MS/MS
Peptide
Score (XC)
Coverage (DeltaCn)
Combined
20.27
KVADEDDVDNEEAALLHEEATMTIEELL TRY
KALEDAFLAIDAKL
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5.47
2.61

0.51
0.33
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Fig. 2-3.
Activation of PP2Ca by short and long chain ceramides in ethanol and
dodecanelethanol delivery systems. A, Recombinant PP2Ca was assayed in the presence of
ethanol, or 30~M C 6 -ceramide solubilized in ethanol as described under 'Experimental
Procedures.' B, PP2Ca was assayed in the presence of dodecane/ethanol or 30~M C 6 -ceramide
delivered in dodecane/ethanol. Data represent mean ± S.E. of four independent experiments. C,
PP2Ca was assayed in the presence of increasing concentrations of C 16-ceramide delivered in
dodecane/ethanol (2%/98%) resulting in an EC so =5.303 +1- 0.328 ~M. Result is representative of
at least 2 experiments. D, Particles were prepared with increasing amounts of C l6 -ceramide
delivered in dodecane/ethanol (2%/98%) for a final concentration of 1% in assay buffer.
Preparations were analyzed by dynamic light scattering for measurement of particle size. Data
represent the average of 2 independent experiments that were measured at least 5 times per
sample.

32

B

A
250
C)

E

c:

~

.

200

0.30

Dod/EtOH

• C 16-Cer

C)

(\')

15
E
a.

Dod/EtOH

0.25

E

c:

0.20

B:

0.15

°E

150

a:

N

•

(\')
(\')

100

l5 0.10

E
a. 0.05

50
0
0.0

o.00 -ft-T-~~.....--.-~--r-~~~~.....--.----r-i
0.5

1.0

MBP

1.5

2.0

2.5

0.0

0.2

0.4
MnC~

(~lM)

0.6

0.8

1.0

(mM)

Fig. 2-4. Effect ojC J6-ceramide on kinetic parameters oj PP2Ca. A , Recombinant PP2Ca was
assayed in the presence of dodecane/ethanol or dodecane/ethanol/C 16-ceramide (30 !-!M) at
varying concentrations of radiolabeled MBP substrate showing a Km of 0.133±0.0739 !-!M and
0.368±0.0556 !-!M and a V max of 26.76±3 .347 pmol 32Pi/min/mg and 231.2±11.29 pmol
32Pi/min/mg for dodecane/ethanol or C 16-ceramide respectively. B , Recombinant PP2Ca was
assayed in the presence of dodecane/ethanol or dodecane/ethanol/C J6 -ceramide (10 !-!M) at
increasing concentrations of MnC1 2 showing a KA of 0 .06348±0 .007045 mM and
0.08169±0.007314 mM and V max of 0.05997±0.007045 pmol 33Pi/min/mg and 0.2835±0 .007276
pmol 33Pi/min/mg for dodecane/ethanol or C 16-ceramide respectively. Data are representative of 2
experiments.
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Table 2-2
Kinetic values of Fig. 2-4A

±

S.E.
Dod/EtOH

V max (pmol 32Pilmin/mg)

26.76

±

3.35

231.2

±

11 .29

0.133

±

0.074

0.368

±

0.056

201.20

Vmax/Km

627.75

Table 2-3
Kinetic values of Fig. 2-4B

±

S.E.
Dod/EtOH

V max (pmol 33Pilmin/mg)

C 16-ceramide

0.05997

±

0.00705

0.2835

0.06348

±

0.02747

0.08169

0.9447

3.470
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0.0073
±

0.00731
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Fig. 2-5. Lipid specificity of activation of PP2Ca. PP2Ca was assayed in the presence of 10 ~M
D-erythro, D-threo, L-erythro, or L-threo-C 16 -ceramide (A); or 10 ~M sphingosine, I-deoxy-C 16 ceramide, dihydro-C 16-ceramide, D-erythro-C I6 -ceramide (B); or 10 ~M palmitate, oleate,
dipalmitoyl-glycerol, or D-erythro-C 16-ceramide (C) as described in 'Experimental Procedures.'
Data represent mean ± S.E. of fold change compared to dodecane/ethanol control of at least 2
independent experiments. Unpaired t-test, * p = 0.023.
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Fig, 2-6, Ceramide-dependent dephosphorylation of phospho-p380. A, PP2Ca actIvIty was
measured as described in 'Experimental Procedures' using recombinant phospho-p386 as
substrate with increasing concentrations of C l6 -ceramide in dodecanelethanol (2%/98%).
Increasing concentrations of C l6 -ceramide were incubated with recombinant p386 with or without
PP2Ca. B, Phosphorylated p386 was quantified from the upper panel including PP2Ca using
ImageJ software. Data represent mean ± S.E. of 4 separate determinations. One-way ANOVA
statistical analysis with Bonferroni's post test, * p<O.Ol, ** p<O.OOl.
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Chapter 3: Essential Role of Acid Sphingomyelinase in Interleukin-6 Synthesis and Cancer
Cell Invasion

Introduction

Interleukin-6 is a paradigmatic cytokine for the connection of inflammation to cancer.
Despite its physiological roles in inflammation and immunology, IL-6 has been increasingly
implicated in essentially all steps of cancer biology(128). The action of IL-6 on STAT3 may be a
common trademark of cancer as a fundamental driver of tumorigenesis and promoter of a
proinvasive microenvironment. IL-6 is capable of sustaining proliferation, promoting invasion,
inducing EMT, and aiding metastasis(129-131).

There is a strong correlation between

invasiveness of cancer cell lines and the level of IL-6 production(132) suggesting that although
IL-6 is capable of being produced by many cell types, tumor-derived IL-6 may be a critical
determinant in a tumor's invasive phenotype.

Sphingolipids have been implicated as regulators of cytokine production, including IL-6,
but most reports have been limited to macrophages or fibroblasts where the role of sphingolipid
catabolism in cytokine production from cancer cells is largely unexplored(59, 66, 133). Previous
work has demonstrated that IL-6 production is regulated by catabolism of glycosphingolipids via
acid f3-glucosidase 1 (GBA) in a negative manner in MCF-7 in response to the tumor promoter,
PMA(62). Metabolically in response to PMA, PKC6 stimulates the hydrolysis of complex SPLs
leading to the production of ceramide from either GBA or acid sphingomyelinase (ASM) leading
to flux through the SPL salvage pathway(9, 10). However, there is a lack of understanding in
regard to the contribution of other sphingolipid enzymes to IL-6.

Here, the roles of sphingolipid salvage enzymes were defined in MCF-7 in response to
the PKC activator, PMA. We identified ASM to be critically involved in IL-6 production, which
was also demonstrated for its mRNA.

Our findings demonstrate that in MCF-7 cells, PKC-
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mediated induction of IL-6 mRNA is mainly a result of increased message stability ~ where ASM
may be playing a role in both stability and transcription. Additionally ~ MCF-7 cells versus MDAMB-231 and He La cells have distinctly different IL-6 RNA dynamics suggesting that invasive
cancer cells have increased basal IL-6 mRNA stability while also capable of eliciting a
transcriptional response to PMA, which begins to reveal the mechanisms involved in IL-6
synthesis from invasive cell lines.

Furthermore, the role of ASM in invasion was assessed

revealing a critical role for ASM in this process in HeLa

cells~

which correlated with IL-6 levels.

Here we show a novel and specific function for ASM as a regulator of IL-6 production and as a
potential factor in mediating a proinvasi ve environment.
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Materials and Methods
Materia ls- Active-p38 (phospho) antibody and p380 antibodies were from Promega (Madison,
WI) and R&D Systems (Minneapolis, MN) respectively. PMA was from Calbiochem (La Jolla).
TNFa was from Pepro Tech.

HRP-linked secondary antibodies were from Santa Cruz

Biotechnology. Actinomycin D and Myriocin were purchased form Sigma. Invasion wells were
from BD Bioscences. Fumonisin B 1 was from Enzo Life Sciences (Farmingdale, NY).

Cell Culture- MCF-7, MDA-MB-231, HeLa, control fibroblasts, and Niemann Pick fibroblasts
were grown in DMEM supplemented with L-glutamine and 10% fetal bovine serum. Cells were
cultured under standard conditions (37C, 5% C02, humidified air) and kept under 90%
confluence. For a 6-well plate, 50,000 cells/well were plated and then the next day transfected
with 20 nM siRNA according to manufacturer's instructions using Oligofectamine (Invitrogen).
After 48 hr, media was changed 1 hr prior to stimulation with either PMA (100nM) or TNFa
(20ng/ml).

Western Blotting- Cells were harvested by direct lysis in 1% SDS/ 1 mM EDTA/ 50 mM Tris
HCI pH 7.4. Lysates were sonicated and total protein was normalized by BCA method. Laemmli
buffer was added (6X) and then samples were boiled for 5 min. Equal volumes were loaded onto
Criterion precast gels and run at 1OOV . Proteins were transferred to nitrocellulose membranes,
....

blocked with 5 % nonfat milk in PBS/O.1 % Tween 20 and were incubated overnight with primary
antibodies in 5 % nonfat milk in PBS/ 0.1 % Tween 20. Membranes were washed in PBS/ 0.1 %
Tween 20 at least 3 times, incubated with secondary antibodies (1 :5000), washed again, and then
developed in ECL chemiluminescence reagent (Pierce).
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Reverse-transcriptase Reaction and PCR- Equal amounts of RNA were isolated (Qiagen, RNeasy

kit) and used in reverse-transcriptase reaction (Superscript II). The final reaction was diluted to 2
mg initial RNA/ml. For qPCR analysis, 5J.lI of cDNA was used per 25J.lI reaction in duplicate or
triplicate using SYBR Green SuperMix (BioRad). Ct values of target genes were normalized to
actin Ct values. Primers for IL-6 were designed using Primer-blast (NCBI) in order to amplify
specifically mRN A (reverse primer aligning to contiguous regions of exon 1 and 2), hnRNA
(reverse primer completely within intron), or both (reverse primer aligning to adjacent exon, exon
2, to the forward primer (exonl» with a common forward primer for these reverse primers. IL-6
primer specificity was validated with melt curves and by DNA electrophoresis. This approach
was feasible due to the relatively small intron found between exons 1 and 2 allowing for efficient
amplification across the intron if present when using the primer set amplifying both species
simultaneously. However, this set was only used when performing semiquantitative-PCR. ASM
and actin primer sequences were described previously(62, 68).

IL-6 ELISA-Cultured media was harvested and IL-6 measured by human IL-6 ELISA according

to manufacturer's protocol (R&D, quantikine). Cellular protein was harvested and measured by
BCA method. IL-6 concentrations were normalized to total cellular protein yielding pg of IL-6/
mg of total protein unless otherwise indicated. In no case did normalization alter the results
significantly ruling out changes in total cell number or protein content as the determinant.

Phase Contrast Microscopy-

Cells were washed with cold PBS and then fixed in 3.7 %

paraformaldehyde for 10 minutes at room temperature. Dishes were aspirated, and washed with
PBS. Images were acquired with a Nikon microscope using PhIl or PhL objectives.
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Confocal Microscopy- Cells were washed with cold PBS, fixed in 3.7 % paraformaldehyde, and
permeabilized in Triton X-lOa for 10 minutes. Samples were blocked in 2% human serum for 1
hr and then incubated with vimentin primary antibody in 2% human serum for 90 min at room
temperature.

Samples were washed and incubated with secondary antibodies conjugated to

TRITC for 1 hr. Samples were washed again and then incubated with DRAQ5 and phalloidin and
wash steps were repeated before imaging on confocal laser microscope (LSM51 a Zeiss).

Invasion Assay-

HeLa cells were treated with siRNA for 72 hrs, trypsinized, and plated in

transwells coated with matrigel in serum free media with either serum free or 10% serum in the
bottom chamber. The cells were allowed to grow and invade for 48 hr and then stained with
flourescein. Four representative images each well were acquired and the number of cells invaded
through the matrigel counted. Cells were plated in triplicate.

ASM Activity Assay- Protein lysates from MCF-7, MDA-MB-231, or HeLa were assessed for
ASM activity as described previously using radiolabeled SM(22).

Statistical Analysis- Statistical and kinetic analysis was performed with Prism/GraphPad using
one phase exponential decay equation for calculating half life of IL-6 mRNA. Results displayed
are means ± S .E. Appropriate statistical tests were performed depending on the experiment with
significance set at a p value of < 0.05.
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Results

Regulation of IL6 production by PKC and SPL enzymesStimulation of the breakdown of complex sphingolipids through the salvage pathway has
been shown to be dependent on PKC6, a novel PKC, in response to PMA in MCF-7 breast cancer
cells(JO). Moreover, activation of ASM directly has been linked to PKC6, leading to ceramide

accumulation(9). Due to the interplay between PKC signaling and sphingolipids, it was relevant
to define the roles of classical and novel PKCs in the context of IL-6 production. Through the
use of inhibitors G66976 (classical PKC inhibitor) and bisindoleilamide (Bis, classical and novel
PKC inhibitor), each class can be tested. It was revealed that novel PKCs are primarily involved
in the production of IL-6 since PMA-induced IL-6 was only blocked by Bis and not G66976 (Fig.
3-1A).

Previous work from our laboratory has shown that catabolism of glycosphingolipids
through acid f3-g1ucosidase (GBA) is required for proper regulation of IL-6 production in MCF-7
breast cancer cells in response to PMA(62). This was demonstrated by showing that loss of GBA
lead to an enhancement of IL-6 production, which was p386 dependent. In order to extend this
work, other enzymes in the sphingolipid salvage pathway were assessed for their contribution to
the regulation of IL-6 production in MCF-7. Using a silencing approach, MCF-7 cells were
treated with siRNA against ACD, ASM, and GBA to compare the roles of these enzymes (Fig. 3IB). As expected, loss of GBA lead to an enhancement of IL-6, though, ASM was found to be
required for IL-6 induction by PMA treatment in contradistinction to GBA. Further, loss of ACD
had no effect on IL-6 (Fig. 3-1B). To test whether ACD is required for the GBA or ASM
response, co-knockdown of these enzymes was tested, demonstrating that in the presence or
absence of ACD, there was a similar fold change in IL-6 upon ASM and GB (Fig. 3-1C).
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Additionally, inhibition of other sphingolipid metabolizing enzymes were tested. Loss of NCD or
SKI had no effect on IL-6 while SK2 siRNA lead to a modest reduction (Fig. 3-1D).
Interestingly, neither ceramide metabolizing enzymes, ACD or NCD, were required for IL-6
suggesting that ASM-derived ceramide is responsible for signaling to IL-6 production. Taken
together, these results demonstrate a complex interplay between PKC6 and sphingolipid
catabolism and also within the SPL salvage system with differential roles for ASM and GBA in
terms of regulation of IL-6. This finding raises the possibility that ceramide derived from either
ASM or GBA could have opposite biological functions while a similar metabolic fate.

Role for ASM in IL6 productionThe finding that ASM was specifically required for IL-6 synthesis in MCF-7 cells lead us
to hypothesize that ASM is critically involved in IL-6 synthesis and related invasiveness of
carcinoma cell lines.

The contribution of ASM to IL-6 production was assessed in invasive

cancer cell lines as it is known that invasive cell lines such as HeLa and MDA-MB-231 make
significantly more IL-6 than MCF-7, where IL-6 is known to play a role in their malignant
properties. Knockdown of ASM by siRNA in HeLa cells resulted in decreased IL-6 production in
response to PMA and TNFa with a trend towards decreasing basally (Fig. 3-2A).

Further,

treatment of MDA-231 and HeLa cells with desipramine (50l-tM), a lysomotropic agent leading to
the degradation of ASM and ACD, resulted in decreased IL-6 production basally and in response
to PMA and TNFa (Fig. 3-2B-C). The previous findings thus far are limited to cancer

cells~

therefore, the role of ASM was tested in fibroblasts, which are IL-6 producing cells but not
malignant. Here we show that in Niemann Pick Disease fibroblasts, which have homozygous
somatic mutations in ASM, there is a profound defect in IL-6 production, basally and in response
to TN Fa (Fig. 3-2D). Therefore, using multiple approaches, this demonstrates that ASM plays an
essential role in IL-6 production in fibroblasts and in noninvasive and invasive cancer cell lines .
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Mechanisms of PMA and ASM in Regulating IL-6 mRNAThe above results show that ASM is involved in IL-6 at the protein level, which is
detected by ELISA in cultured media. Therefore, we aimed to determine at which point in the
pathway of IL-6 production does ASM intervene, as several possibilities could explain the above
results including altered secretion, translation, or transcription. In order to divide these possible
mechanisms, the roles of ASM and PMA in regulating IL-6 mRNA were first assessed.
Knockdown of ASM resulted in a robust decrease in PMA-induced IL-6 mRNA expression (Fig.
3-3A). This finding suggested that translational or secretory regulation of IL-6 by ASM/ceramide
was unlikely, while pointing towards altered IL-6 RNA dynamics.

Levels of mRNA are a function of its synthesis, dictated by transcription and subsequent
processing, and also its degradation(134), where both of these processes (transcription and
degradation) are known to be regulated steps for IL-6 RNA(135, 136).

Further, levels of

heteronuclear RNA (hnRNA) are essentially a function of transcriptional rates if processing is
assumed to be constant, and can be measured by amplifying with at least one primer aligning to
intronic sequence(134). So by measuring hnRNA and mRNA, transcriptional and stabilizing
effects can be distinguished without manipulation of the system. To understand how PMA is
affecting IL-6 mRNA dynamics, MCF-7 cells were treated with PMA at 45 and 90 minutes and
subsequently IL-6 hnRNA and mRNA levels were measured by specific primers for each species.
PMA treatment had no effect on hnRN A levels yet resulted in a robust upregulation of IL-6
mRNA indicative of increased message stability by PKC activation (Fig. 3-3B). To demonstrate
this further, an Actinomycin D timecourse was employed to assess the decay rate of IL-6 mRNA
in PMA and ASM knockdown cells. PMA treatment resulted in a modest increase in message
stability, yet considerable variability was noted (Fig. 3-3C). Loss of ASM modestly decreased
mRNA stability in control and PMA treatment. On the other hand, ASM knockdown caused a

4S

modest decrease in hnRNA as well (Fig. 3-S4). This suggests that ASM may be involved in
stability as well as transcription of IL-6 mRNA. Taken together, PMA induction of IL-6 mRNA
is primarily a function of increased stability of its mRNA, where ASM is likely involved in
stability with a minor role in transcription.

ASM knockdown was tested on levels of IL-6 mRNA in HeLa and MDA-MB-231 cells
to address the role of ASM in regulating IL-6 mRNA in invasive cancer cells. Inhibition of ASM
had either no effect or a trend towards a decrease in IL-6 mRNA although not significant (Fig. 34A-B).

The lack of effect by ASM siRNA could potentially be explained by insufficient

silencing of ASM message (Fig. 3-S3B). Nevertheless, NPD fibroblasts had a dramatic decrease
in IL-6 mRNA basally and with TNFa treatment (Fig. 3-4C). To assess the IL-6 RNA dynamics
in HeLa and MDA-MB-231, a similar approach as in MCF-7 was used with PMA treatment.
Addition of PMA resulted in induction of hnRNA with a peak at 45 minutes preceding the
accumulation of mRNA at 90 minutes (Fig. 3-4D-E). This pattern is in distinct contrast to MCF7, where PMA had no effect on hnRNA. Furthermore, MDA-MB-231 cells are known to have
dramatically more basal or background IL-6 mRNA and protein than MCF-7.

In order to

understand this dramatic upregulation, hnRNA and mRNA levels were compared between the
cell lines in unstimulated conditions (Fig. 3-4F). MCF-7, MDA-MB-231, and HeLa cells were
found to have comparable levels of hnRNA despite the striking difference of mRNA pointing
towards an altered basal stability of IL-6 mRNA in MDA-MB-231 and HeLa. Moreover, by
performing semi-quantitative PCR with primers that flank an intron, thereby amplifying both
hnRNA and mRNA together, MCF-7 cells were demonstrated to have more hnRNA than mRNA
basally where MDA-MB-231 and HeLa have more mRNA (Fig. 3-S2) reinforcing the differences
in basal IL-6 RNA dynamics between the cells.
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Based on the substantial increase in IL-6 observed in MDA-MB-231 and HeLa over
MCF-7, we hypothesized that these invasive cell lines may also possess increased levels or
activity of ASM. Levels of ASM mRNA were measured, which revealed an upregulation of
ASM expression in MDA-MB-231 and HeLa compared to that of MCF-7 (Fig. 3-5A).

Regulation of p38 by ASM was evaluated since p38 is known to be involved in both
transcriptional and stabilizing responses for IL-6(52, 54, 136). Knockdown of ACD, ASM, or
GBA in MCF-7 cells resulted in a differential pattern of PMA-induced p38 phosphorylation
similar to that of IL-6, where loss of ASM blunted p38 phosphorylation (Fig. 3-6A). This was
also seen in HeLa in response to PMA (Fig. 3-6B). Furthermore, inhibition of ASM with either
siRNA or desipramine in HeLa largely blocked TNFa-dependent phosphorylation of p38.
Preliminary data suggests that ASM is also regulating MKK3/6 phosphorylation, an upstream
kinase of p38, in HeLa (data not shown). It is unknown how ASM/ceramide is involved in p38
activation. A few possibilities include direct involvement in upstream signaling to p38 perhaps
even regulating PKC; alternatively loss of ASM could disrupt trafficking or translocation of p38
to be in proximity to upstream signals. Additionally, ASM could playa role in the coordination
of protein complexes since p38 MAPK pathways are known to require the assembly of protein
scaffolds.

Role of ASM in Cancer Cell InvasionDue to the abundant evidence linking IL-6 to proinvasive biological processes, we
wanted to assess the role of ASM in HeLa cell invasion. Knockdown of ASM resulted in a
dramatic decrease in invasion through matrigel (Fig. 3-7 A). ASM was also required for invasion
in MDA-MB-231, suggesting that ASM could be playing a fundamental role in the pathological
process of invasion (data not shown).

Additionally, loss of ASM resulted in a noticeable
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morphological change in HeLa, causing a more cuboid appearance lacking prominent cell
protrusions and an appreciable loss of F-actin stress fibers (Fig. 3-7C and Fig. 3-S6). This did not
correlate with changes in the mesenchymal marker, vimentin, ruling out a reversal of EMT, but
large changes in phosphorylation of myosin light chain (MLC) were noted upon ASM
knockdown in MDA-MB-231 and HeLa (Fig. 3-S7). Taken together this shows a role for ASM
in mediating invasion in invasive cell lines, which is consistent with its role in regulating IL-6.
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Discussion

In this study we defined a role for ASM in regulating the proinvasive cytokine, IL-6, in
cancer cells with potential implications for ASM in IL-6-related cancer progression.

This

function of ASM was specific to ASM since other salvage pathway enzymes did not have similar
roles in regulating IL-6. ASM was demonstrated to play an important role in IL-6 production at
the protein level in MCF-7 breast carcinoma cell lines and then also in invasive cancer cells and
fibroblasts.

It was found that in MCF-7 cells, PMA and ASM primarily induce IL-6 by

increasing mRNA stability. By investigating mRNA dynamics between MCF-7, MDA-MB-231,
and HeLa cells in response to PMA, distinct IL-6 mRNA profiles were demonstrated basally and
in response to PMA. Additionally, ASM was shown to be critically involved in invasion of HeLa
cells, a process that is related to IL-6.

PKC and Sphingolipid Metabolism in IL-6 RegulationThe finding that novel PKCs are required for IL-6 production is consistent with the role
of PKCb in ASM activation(9), where ASM was here found to also be essential for PMA-induced
IL-6 (Fig. 3-1A). It is unclear if PKCb, also stimulating catabolism of glucosylceramide via
GBA(lO), would also have a function in negatively regulating IL-6. A negative role for PKCb

has been shown for p38 phosphorylation with using PKCb siRNA(62). It is possible that this
apparent discrepancy is due to compensation or enhanced PKC signaling of other isoforms under
PKCb knockdown conditions, where this effect is ruled out when using G66976 and Bis.
Additionally, it is unclear in our studies if ASM is actually mediating the effects of PMA and
PKC. In Fig. 3-1B, there is clearly a dependence of ASM for PMA-induced IL-6 suggesting a
requirement of ASM.

However, in many other cases, ASM is regulating both the basal and

stimulated levels of IL-6 protein and mRN A, where the fold induction in response to PMA or
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TNFa are similar to that of the control. This suggests that in some scenarios ASM and PKC may
be in parallel but distinct pathways, converging on IL-6.

In terms of sphingolipid metabolism, it is surprising that loss of ACD or NCD has no
effect on IL-6, yet loss of ACD does have a trend towards increasing IL-6 in MCF-7 (Fig. 3-1B);
however, other ceramidases (ACERs) may be relevant in this context. Loss of ACD may have a
neutral effect since it is also blocking GBA-derived ceramide from further metabolism. Since,
loss of ACD has the trend towards an increase, it is possible that ASM-derived ceramide may
override the inhibition of GBA-ceramide suggesting that ASM/ceramide pathway may act
downstream of GBA/ceramide where both ceramides would potentially be accumulated upon
ACD knockdown.

This raises the possibility of a novel paradigm that not only the topology of a
sphingolipid is important but within that subcellular location, the enzyme from which it is
produced may dictate its function. This model is supported by a few lines of evidence. It can be
concluded that the bioactive lipid with GBA and ASM is likely to be upstream of ACD since their
functions were not dependent on ACD (Fig. 3-1 C) ruling in that ceramide derived directly from
GBA or ASM are bioactive but having opposite functions on IL-6: GBA-derived ceramide a
negative regulator and ASM-derived ceramide a positive regulator.

Metabolic studies have

shown that C 16-ceramide is the predominant ceramide species accumulated in response to PMA
and that this is partially dependent on both GBA and ASM(lO). This suggests that the ceramide
derived from either ASM or GBA, though identical in chemical structure, has distinct functional
coupling. Based on our studies, the subcellular topology was not defined, but we speculate that
ASM and GBA are acting on the SM and GC pool at the plasma membrane, respectively. In
terms of transducing a signal, the plasma membrane is a more likely candidate than the alternative
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option, the lysosome, which is encased by the limiting membrane, where ASM and GBA are in
the lumen, degrading internal membranes engulfed by the lysosome. With respect to how ASM
and GBA could be localized to the plasma membrane, it is possible that it is due to a change in
sorting from lysosomal targeting to the secretory pathway in the Golgi(9, 22) or a direct
translocation from endosomalllysosomal compartments to the plasma membrane(9).

Regulation of Cytokine Production by ASM-

Previous reports have studied cytokine regulation by ASM with varying results. This is
likely due to the use of various approaches and distinct pathways for difference cytokines.
Studies with macrophages have used ASM-1- peritoneal macrophages or an ASM inhibitor, SMA7 with opposing results(59, 66, 133). There is an emerging theme that complete loss of ASM
activity may have different biological effects than partial or incomplete loss of activity. This
concept has been demonstrated for ASM in mouse models in liver fibrosis where ASM+1- are
protected but ASM-1- are susceptible to fibrosis(137, 138). The complete loss likely leads to
global lysosomal dysfunction due to excessive SM accumulation. More recently, a study showed
involvement of ASM in IL-6 production in response to carcinogenic electrophiles but not TNFa
alone in bladder cancer cells where these electrophiles resulted in ASM upregulation(139).
Despite clear roles for ASM in IL-6 regulation at the mRNA level it is still unclear how this
occurs mechanistically. There are varying reports of ceramide activating p38 signaling, but there
is no strong consensus as to the mechanism for this(59, 60, 140, 141). Our results do show a role
for ASM/ceramide in p38 activation in MCF-7 and HeLa cells although the mechanism is
unknown.

Previous work from our lab has demonstrated a role for both, ASM and ACD in the
production of the chemokine, CCL5/RANTES(68), which is likely to be a distinct pathway of
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regulation from ASM and IL-6.

This concept is supported by the requirement of ACD for

RANTES, where loss of ACD trended towards an increase in IL-6 production distinguishing
these two systems. One explanation of this finding is that these cytokines are distinct in their
expression pattern in response to TNFa, IL-6 being rapidly induced and RANTES possessing
slower kinetics(142). Also IL-6 mRNA is unstable containing multiple 3' UTR AREs and is
regulated substantially by increases in stability where RANTES mRNA is intrinsically very
stable(142). It is possible that there is a coordinated regulation of these classes of cytokines by
sphingolipids, particularly ceramide and sphingosine. Ceramide, produced first metabolically,
may be critical for IL-6, which is induced acutely, and then accumulation of sphingosine may
trigger the transition to induction of late response genes such as RANTES.

Implications for Cancer BiologyDue to the accumulating evidence for IL-6 as a critical player in cancer biology, targeting
pathways that are involved in IL-6 synthesis or downstream effects may prove to be a powerful
approach for attenuating invasion and metastasis(128, 143). Inhibition of ASM could be a simple
and effective way to block IL-6 produced in the microenvironment by tumor cells, which is
required for invasion.

Mechanistically, this work reveals key differences in IL-6 mRNA dynamics between
MCF-7, MDA-MB-231, and HeLa cancer cells, the later two being invasive. First, there were
similar basal steady state levels of hnRNA between the cell lines suggesting that transcriptional
activity is equivalent, yet basal steady state levels of mRNA were orders of magnitude increased
in MDA-MB-231 and HeLa over MCF-7.

This increase in steady state of mRNA could be

explained by increased transcription or increased stability; however, since hnRNA levels are
roughly equivalent, an increase in basal stability possibly explains the differences in mRNA.
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Second, MCF-7 cells did not display any induction of IL-6 hnRNA in response to PMA where the
other cell lines did, demonstrating that these invasive cell lines have gained the ability to elicit a
transcriptional response. Epithelial cells typically are not producers of large amounts of IL-6,
which suggests that MDA-MB-231 and HeLa have a gain of function that allows for them to
produce IL-6 constitutively in large levels and also in response to cytokines. What process is
responsible for this is not known but possibilities include EMT or activating Ras mutations.
Additionally, the role of ASM in this process is still to be determined, which may be significant
since it is upregulated in these cells (Fig. 3-5).

This work suggests that there are differing

mechanisms responsible for changes in basal and stimulus-dependent IL-6 production as cancer
cells become more invasive.

In summary this work demonstrates a clear role for ASM in the regulation of IL-6
production in normal and cancer cells.

This regulation is specific in that other sphingolipid

salvage pathway enzymes did not replicate this. Loss of ASM was found to be essential for p38
activation as well, defining a role in upstream signaling to IL-6. Moreover, ASM may playa
critical role in mediating the increased levels of IL-6 found in invasive cell lines. In line with
this, ASM was required for invasion of HeLa cells. For the first time, this implicates ASM as a
positive regulator of malignant cancer properties. Further investigation is needed to understand
how ASM is mediating its effects on p38 and IL-6.
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Fig. 3-1. Regulation of IL-6 Production by PKC and Sphingolipids: Requirement of ASM. A,
PKC inhibitors G66976 and Bis (3!J,M) were added to subconfluent MCF-7 cells for a 1 hr.
pretreatment following PMA (1 OOnM) treatment for 18 hr. IL-6 was measured by ELISA in
cultured media. (t-test, *** p<O.OOI, n=2). Band D, MCF-7 cells were treated with 20nM
siRNA for the labeled enzymes for 48 hr and then stimulated with PMA for 18 hr (two-way
ANOVA, Bonferroni's post-test, ** p<O.OI, *** p<O.OOI, n=3 (B), n=1 (D)). C, MCF-7 cells
were cotreated with siRNA for the above enzymes for 48 hr followed by PMA treatment for 18
hr. Fold change was calculated to either control siRNA or ACD siRNA alone for each group
(n=2).
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Table 3-1:

IL-6 peR primers
Primer
Forward
hnRNA Reverse
mRNA Reverse
hn/mRNA Reverse

sequence (5' to 3 ')
CGA GCC CAC eGG GAA eGA AA
eCA GGG eTA AGG ATT Tce TGe ACT T
TGG Ace GAA GGC GCT TGT GGA
CAG CCC CAG GGA GAA GGC AAC T
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Fig.3-S6. HeLa cells transfected with control, ASM, or GBA siRNA for 48 hr were visualized
by immunofluorescence for vimentin (green), F-actin (red, phalloidin), nuclei (blue, DRAQ5).
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Chapter 4: Concluding Discussion

Summary and Future Directions
In the past decades, our understanding of sphingolipids' roles and mechanisms have
grown immensely based on paradigm shifts including the discoveries that synthesis and
breakdown of sphingolipids by their metabolic enzymes are regulated steps and that sphingolipids
contain bioactive properties and also due to advances in the research tools to probe these systems
including lipidomic mass spectrometric analysis, highly quantitative and specific radioactive
activity assays for the various enzymes, genetic knockout mouse models, and validated RNA
silencing technology. With the existing and forthcoming tools, we are only beginning to see and
understand the biological functions of many of these enzymes including GBA and ASM. The
overall goal of this work was two fold: I) To identify novel signaling targets of ceramide, which
could further unravel the mechanisms by which ceramide mediates its biological effects and 2) To
define the contribution of specific salvage pathway enzymes in the regulation of IL-6 in the
context of cancer biology.

Ceramide-Activation of PP2C
In an effort to further understand direct targets of ceramide signaling, a novel class of
ceramide-activated protein phosphatases was identified as PP2C.

From a high-salt fraction,

PP2Cy was identified by proteomic analysis and was shown to be ceramide-activated yet Okadaic
acid-insensitive, consistent with it being in the PPM/PP2C family.

Using PP2Cu for further

characterization it was shown that this activation was specific for the erythro conformation of
ceramide and possessed a high degree a lipid selectivity for ceramide over sphingosine, I-deoxyceramide, fatty acids, and diacylglycerol.

Activation by ceramide primarily is mediated by

enhanced catalytic rate evidenced by increases in V max and no decrease in Km or K A •
Additionally, ceramide was sufficient to induce the dephosphorylation of p380 by PP2Cu, a
physiological substrate. The implications of this work are that ceramide and PP2Cu are directly
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interacting in some fashion. In line with this, a hydrophobic surface plot of PP2Ca's crystal
structure exhibits a handful of intriguing hydrophobic crevasses, which could be ideal for
interaction with ceramide. Specifically, we suspect the headgroup of ceramide being involved in
this interaction which possesses a hydroxyl group and an amide linkage suggesting that the
putative pocket in PP2Ca is not purely hydrophobic at the 'base' of the pocket but then
hydrophobic regions would interact with the hydrocarbon tails.

Remaining goals include I-further understanding the biophysical interaction between
ceramide and PP2C and 2-developing the biological significance of this interaction.
1.

Activation of PP2Ca was demonstrated with ceramide when delivered In either in

ethanol or dodecane/ethanol but not when prepared in liposomes or Triton X-100 micelles
(Fig. 4-1).

This finding begs the question as to the nature of ceramide particles when

prepared in ethanol or dodecane/ethanol and then added to an aqueous buffer. There is very
little knowledge on this topic and would be significant for understanding the nature of
activation of PP2C and also PP2A/PP 1. Performing differential scanning calorimetry in order
to detect a phase change upon the addition of ceramide would further address the nature of
the lipid particle being made in this system. Also using dodecane may be problematic as it
does effect basal activity of PP2ca (ethanol 1% does not) and possibly effects linearity of
activity

at

low

concentrations

of

protein.

Interestingly,

it

was

found

that

ceramide/dodecane/ethanol preserved linearity at these low amounts of protein (Fig. 4-2).
2.

An outstanding goal is demonstrating a biological context in the cell for cerami de and

PP2C.

Attempts at showing connections between ceramide and PP2C were unsuccessful

(Fig. 4-3 and Fig. 4-4).

Published substrates for PP2Ca include p38, JNK MAPKs,

SMAD2/3, and Axin. Future work is needed to implicate ceramide in possibly SMAD2/3 or

AxinlWnt signaling. An alternative angle on this is related to the finding that PP2Ca is
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myristoylated(144).

Often myristoylation is a prerequisite for palmitoylation, which is

sufficient to embed proteins into the membrane(145). Preliminary results show that an upper
band of PP2Cu is in fact predominantly localized to the insoluble fraction, which may reside
in the nucleus (Fig. 4-5).
myristoylation of G

This upper band is consistent with a shift that is seen with

Ui2

and also affecting its localization to soluble and pellet fractions in an

identical manner(146).

Future work includes demonstrating the exact nature of the

modifications of PP2Cu and then also the physiological role of this modification, which may
be important for its function in the nucleus where it is thought to dephosphorylate
SMAD2/3(127).

Moreover, lipidation and subsequent anchoring in the membrane would

place PP2Cu in proximity to ceramide.

Regulation of IL-6 by Sphingolipids
Despite several reports of sphingolipid involvement in the regulation of IL-6 and
associated signaling pathways, a clear demonstration based on multiple approaches and systems,
defining specific roles of sphingolipid metabolizing enzymes was lacking.

Utilizing MCF-7

breast cancer cells, which have very low background IL-6 making it a very clean system to study
PMA-induced IL-6, we found differential regulation of IL-6 by the salvage pathway enzymes
ACD, ASM, and GBA. ASM was required for IL-6 synthesis in contradistinction to GBA, which
is known to be a negative regulator of IL-6.

ASM was confirmed to be essential for IL-6

production in mUltiple cell lines with different loss of function approaches. Furthermore, the role
of ASM and PMA in affecting IL-6 RNA dynamics was assessed by using a novel qPCR based
approach(147) and traditional actinomycin D methods for measuring stability. It was revealed
that PMA treatment of MCF-7, solely affects stability of IL-6 mRNA having no effect on levels
of newly transcribed hnRNA. ASM appears to be involved in the stability of IL-6 mRNA while
also playing a role in transcription since ASM knockdown did modestly decrease IL-6 hnRNA
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levels independently of PMA. When this same approach was applied to

transformed~

invasive

cancer cell lines, MDA-MB-23I and HeLa, a very different profile was found basally and in
response to PMA. Additionally, ASM is required for invasion of HeLa cells demonstrating a
direct and novel pathophysiological connection to cancer biology.

Future directions in this context include I-defining the mechanisms by which ASM is
mediating its effect on IL-6 and p38 and 2-investigating ASM as a player in metastasis and
invasion in vivo.
1.

Our data shows a role for ASM in p38 activation In MCF-7 and HeLa where it is

unknown how this is mediated. Additionally, one could ask whether p38 is required for ASM
regulation of IL-6 or if constitutively active p38 could rescue IL-6 production upon loss of
ASM? Characterizing a gain of function for ASM on IL-6 would be very helpful in this
scenario although this has not been successful thus far (Fig. 4-6).

Advancement of this

direction would be significant for understanding the actual mechanisms downstream of ASM
and ceramide.
2.

Since ASM was required for invasion of HeLa cells and plays a role in IL-6 a proinvasive

cytokine, it would be natural to assess the role of ASM in cancer biology in vivo. ASM has
mainly been viewed as a mediator of stress responses in terms of cell death thus its role as a
possible mediator of invasion or transformation has largely been ignored. Also the finding
that ASM is upregulated in MDA-MB-23I cells further suggests a potential role in this
process. Specific questions in this regard are I-Is ASM activity increased in tumor tissue or
metastatic foci compared normal tissue? 2-Is ASM required for tumorigenesis andlor
metastasis in vivo? 3-What other pathways or secreted factors are regulated by ASM in the
tumor microenvironment?
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Significance
As a result of this work steps have been made in our understanding of the mechanisms
and roles of ceramide-mediated biologies.

One of the major unanswered questions in the field regarding ceramide is the lack of a
clear and unifying mechanism for ceramide. Activation of the phosphatases PPI/PP2A is clearly
a strong candidate as their activation is consistent with a handful of physiological examples since
their discovery nearly 20 years ago. Progress has been hampered though due to the presence of
several regulatory subunits for these phosphatases, which may in fact be the target of ceramide.
The simplicity of PP2C, being a monomer, is that at least activation by ceramide is definitively a
result of the interaction between the two, albeit in vivo, other scenarios are possible. Ceramideactivation of PP2C may prove to be a mechanism that continues to unravel the mechanisms of
ceramide.

Furthermore, by defining ASM to be involved in IL-6 production and p38 activation a
framework for continuing the studies of ASM is established. Since IL-6 is involved in a plethora
biological processes and diseases, there is a rationale to investigate ASM in the context of these
IL-6 related pathologies.

Specifically, Multiple Myeloma and Rheumatoid Arthritis are both

diseases where IL-6 has been strongly implicated in the pathogenesis; therefore it would be of
interest to investigate the role of ASM in IL-6 production in disease cell types such as synovial
fibroblasts(148,149).

In regard to cancer biology, this work reveals that the dramatic increase in IL-6 at the
protein level and message level found in invasive cell lines is due to primarily increased message
stability.

Moreover, the response to PMA is distinctly different as well. PMA induces IL-6

mRNA solely by a mechanism involving increased stability where in MDA-MB-231 and HeLa
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there is a transcriptional response. One could speculate that PMA in MCF-7 is mimicking the
state of the transformed cell lines. There is a clear gain of function in the ability to initiate a
transcriptional response to PMA MDA-MB-231 and HeLa.

This elucidates the altered

mechanisms for the basal upregulation of IL-6 found in transformed, invasive cell lines and the
response to PMA. Therefore, could targeting the pathway that is responsible for the stability of
IL-6 mRNA in invasive cancers render them noninvasive thereby preventing metastasis?

Conclusion
Here we report a novel target for ceramide, PP2Ca, with implications for ceramide signaling and
a specific function for ASM in mediating IL-6 production with potential roles in cancer biology.
As a result of this work, we understand more fully the mechanisms and roles of sphingolipidmediated biologies with implications to cancer pathogenesis and other IL-6 related disorders.
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